In GBM, it is also notable that PC/SMCs play a pivotal role in the vessel development, as multiple agents targeting PDGF-B/PDGFR-β signaling have been utilized in pre-clinical and clinical trials to inhibition of tumor angiogenesis. Here, PDGFRB is linked to neoplasm.